Emerging Company Profile
Tyra: designing kinase inhibitors resistant to mutations
Emerging Company Profile: Tyra’s crystal structure generation platform accelerates design of kinase inhibitors resilient to resistance mutations
Tyra’s speedier X-ray crystal structure data generation is accelerating its R&D on kinase-targeting small molecules not susceptible to acquired cancer drug-resistance mutations.
Tyra is using its platform for rapidly generating X-ray crystal structures to accelerate the design of targeted small molecule kinase inhibitors that aren’t